ArticleAdvances in therapy2026
Gastrointestinal Symptoms and Abnormal Liver Biochemistry in Patients with COVID-19 Pneumonia Admitted to the Department of Gastroenterology After Ending Zero-COVID Policy in China.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with coronavirus disease 2019 (COVID-19) can present with gastrointestinal symptoms and abnormal liver biochemical tests, but their prevalence and impact on outcomes remain controversial among studies. Importantly, the relevant data are very scarce after the end of the zero-COVID policy in China.
methodsIn this single-center retrospective cohort study, all patients with COVID-19 pneumonia who were consecutively admitted to the Department of Gastroenterology of a tertiary hospital from December 20, 2022 to January 20, 2023 were collected. Differences in gastrointestinal symptoms and abnormal liver biochemical tests were evaluated between patients with moderate and severe/critical COVID-19 pneumonia. Their association with the composite endpoint, defined as transfer to intensive care unit, mechanical ventilation, and/or death, was evaluated by logistic regression analyses.
resultsOverall, 78 patients with COVID-19 pneumonia were included, of whom 49 (63%) had gastrointestinal symptoms, but 13 of them did not have any obvious respiratory symptoms, while 67 (86%) patients had abnormal liver biochemical tests. Compared with patients with moderate COVID-19 pneumonia, patients with severe/critical COVID-19 pneumonia had significantly higher proportions of anorexia (P = 0.041), serum albumin level < 40 g/L (P = 0.010), alanine transaminase level > 40 U/L (P = 0.037), and γ-glutamyl transferase level > 45 U/L (P = 0.038). Constipation [odds ratios (OR) = 23.833, P = 0.019] and aspartate transaminase (AST) level > 35 U/L (OR = 31.085, P = 0.015) were independently associated with a higher risk of composite endpoint among patients with COVID-19 pneumonia.
conclusionsGastrointestinal symptoms and abnormal liver biochemical tests are very common in patients with COVID-19 pneumonia who were admitted to the department of gastroenterology, and constipation and AST level > 35 U/L can independently predict worse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.